Anton Rx Report

There has been scant news over the past year about big moves involving sales and strategic acquisitions in the specialty pharmacy space.  Today my internet

Earlier this week we sent a Report outlining why the term ‘BioBETTER’ should be added to your pharma vocabulary. Today we introduce a new biosimilar that

What is a Biobetter? An article published by the Center for Biosimilars used a new word to the specialty pharmacy lexicon…… BioBetter….. prompting us to

Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely

There was a flood of media coverage following the FDA’s announcement that they have approved Florida’s request to import low-cost drugs from Canada. While that may

………. Catching up on FDA approvals The FDA approved a new therapy at the tail end of last year (it was November and, yes, we are

Happy New Year….. or to be said otherwise, What’s Happy About It? The article below doesn’t trumpet the benefit of the changes implemented by Congress

…..catching up on FDA Approvals The FDA has approved a new subcutaneous therapy, Zilbrysq (zilucoplan) from UCB, for the treatment of adults with generalized myasthenia

Specialty pharmacies produce a lot of reporting…… but, the scope of this reporting may be missing the mark in the evolving competitive marketplace. The real challenge

Another milestone has been passed in the advancement of specialty pharmacy therapies. The FDA has approved not one, but two, gene therapies for a major disease,